Intervention review — page 4
A review of the effects of an intervention on pre-specified outcomes, with a quantitative synthesis where the contributing studies are sufficiently similar.
Reviews
-
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Kisspeptin-10 compared with the comparator used in its contributing trials on the anchor outcome for this…
Moderate11 Oct 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Larazotide acetate compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate01 Mar 2025 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate04 Sep 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Liraglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High20 Apr 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Maridebart cafraglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Low13 Nov 2024 -
In the population defined for obesity and overweight in adults, what is the effect of Petrelintide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Low19 Jan 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the effect of PT-141 (bremelanotide) compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate04 Feb 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate10 May 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this…
High04 Jul 2026 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate14 Apr 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide, oral compared with the comparator used in its contributing trials on the anchor outcome for this…
Moderate01 Nov 2025 -
In the population defined for cognitive performance and neuroprotection, what is the effect of Semax compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Very low26 Dec 2024 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the effect of SS-31 (elamipretide) compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate11 Nov 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the effect of Tesamorelin compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate19 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this…
Moderate13 Nov 2025 -
In the population defined for obstructive sleep apnoea with obesity, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High27 Sep 2025
page 4 of 4